Researchers discover new biomarker to predict multiple sclerosis progression

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple sclerosis (MS).

The thickness of the inflammatory cell rim surrounding brain lesions was found to directly correlate with the severity and speed of disease progression. The study, led at the University of Turku in Finland by Professor Laura Airas in collaboration with German and Dutch colleagues, has been published in the prestigious journal Nature Medicine.

Better targeted treatments and faster drug development

The research combined PET imaging data from 114 Finnish MS patients with post-mortem brain tissue analysis from Dutch MS patients. Results show that the wider the inflammatory rim around a brain lesion is, the more aggressively the disease advances.

When microglial cells form a thick rim around MS lesions, their harmful activity pushes deeper into healthy brain tissue, causing irreversible damage.

This discovery allows us not only to identify patients who need more aggressive treatment earlier but also to evaluate the effectiveness of new drug candidates by observing changes in lesion rims."

Professor Laura Airas, University of Turku

The findings are expected to improve the development of treatments particularly for progressive MS, the yet undertreated form of the disease. 

Source:
Journal reference:

Klotz, L., et al. (2025). Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nature Medicine. doi.org/10.1038/s41591-025-03625-7.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Age and sex shape Alzheimer’s blood biomarkers, study finds